Global biopharmaceutical company Octapharma has announced a $1.5 billion investment to establish its first U.S.-based manufacturing and production facility at Palmetto Research Park in Rock Hill, South Carolina.
The state-of-the-art facility is expected to create 1,500 full-time jobs and will manufacture plasma-derived therapies, including critical medicines for patients with rare and chronic conditions. The site will also produce bleeding management and trauma care products, strengthening U.S. national security and emergency preparedness.
Key Highlights:
✅ Investment: $1.5 Billion
✅ Location: Rock Hill, South Carolina, USA
✅ Employment: 1,500 New Jobs
✅ Industry: Biopharmaceutical Manufacturing
✅ Products: Plasma-derived therapies, bleeding management & trauma care solutions
South Carolina was selected due to its advanced manufacturing ecosystem, strong logistics connectivity, access to deep-water ports, and a skilled life sciences workforce supported by leading universities and technical colleges.
According to CEO and Chairman Wolfgang Marguerre, the new facility represents a major milestone in expanding Octapharma’s manufacturing capacity while enhancing the resilience of the U.S. biomedical supply chain through domestic production of life-saving therapies.
This investment highlights the continued trend of global life sciences companies expanding manufacturing footprints in the United States to strengthen supply chain resilience, support healthcare security, and meet growing global demand.
#Manufacturing #Biopharma #LifeSciences #Healthcare #Investment #SouthCarolina #AdvancedManufacturing #SupplyChain #IndustrialGrowth #EconomicDevelopment #Jobs #IndustrialBuzz